Literature DB >> 28461000

Potential Sunitinib-Induced Coronary Artery and Aortic Dissections.

Raja Hatem1, Emmanuel Bebawi2, Erick Schampaert2.   

Abstract

Small-molecule multitargeted tyrosine kinase inhibitor (TKI) therapy is used in different types of cancer. These drugs have been associated with cardiovascular toxicity, including aortic dissection. To our knowledge, this is the first time that a coronary dissection potentially associated with a TKI treatment has been described. Crown
Copyright © 2017. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28461000     DOI： 10.1016/j.cjca.2017.03.002

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


  4 in total

1.  Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma.

Authors:  Phillip J Groden; Thomas C Lee; Shamik Bhattacharyya; Jean Connors; Jochen Lorch
Journal:  Front Med (Lausanne)       Date:  2018-02-23

2.  Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis.

Authors:  Michael Dörks; Kathrin Jobski; Stefan Herget-Rosenthal; Falk Hoffmann; Antonios Douros
Journal:  Pharmacol Res Perspect       Date:  2021-02

3.  Aneurysm and Artery Dissection Following the Use of Vascular Endothelial Growth Factor Inhibitor: A Real-World Analysis Using a Spontaneous Reporting System.

Authors:  Shuyue Wang; Mingzhu Chen; Xinghui Zhang; Lingjian Zhang; Min Jia; Zhiwen Shen; Junyan Wang; Bin Zhao; Yang Gong; Jian Gong
Journal:  J Am Heart Assoc       Date:  2021-11-30       Impact factor: 6.106

4.  Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma.

Authors:  Bailing Jiang; Junhe Li; Jun Chen; Xiaojun Xiang; Jianping Xiong; Jun Deng
Journal:  Thorac Cancer       Date:  2019-12-31       Impact factor: 3.500
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.